Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Sky One Announces Two More Approvals

publication date: Dec 16, 2008

China Sky One Medical (中国天字一号医药公司) is having a strong year-end finish in its new-product onslaught.  Today, the company announced SFDA production approval for two additional drugs, after receiving production approval for two other new products last week.  The most recent approvals are for Sodium Cromoglicate Eye Drops, a treatment of allergic conjunctivitis, and Ftibamzone Liniment a treatment of herpes and fungal skin infection.  The new products will be launched early in 2009. More details...

Stock Symbol: (NSDQ: CSKI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital